WallStSmart

GE Vernova LLC (GEV)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 64% more annual revenue ($62.58B vs $38.07B). GEV leads profitability with a 12.8% profit margin vs 12.4%. GEV appears more attractively valued with a PEG of 3.34. GEV earns a higher WallStSmart Score of 55/100 (C-).

GEV

Buy

55

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 2.7Quality: 4.3
Piotroski: 4/9Altman Z: 1.02

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GEVOvervalued (-6.0%)

Margin of Safety

-6.0%

Fair Value

$829.76

Current Price

$923.69

$93.93 premium

UndervaluedFair: $829.76Overvalued
PFESignificantly Overvalued (-194.9%)

Margin of Safety

-194.9%

Fair Value

$9.25

Current Price

$27.28

$18.03 premium

UndervaluedFair: $9.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEV3 strengths · Avg: 9.3/10
Market CapQuality
$246.74B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
42.6%10/10

Every $100 of equity generates 43 in profit

Free Cash FlowQuality
$1.81B8/10

Generating 1.8B in free cash flow

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.36B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

Areas to Watch

GEV4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
3.8%4/10

3.8% revenue growth

PEG RatioValuation
3.342/10

Expensive relative to growth rate

P/E RatioValuation
51.3x2/10

Premium valuation, high expectations priced in

Price/BookValuation
22.3x2/10

Trading at 22.3x book value

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : GEV

The strongest argument for GEV centers on Market Cap, Return on Equity, Free Cash Flow.

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bear Case : GEV

The primary concerns for GEV are Revenue Growth, PEG Ratio, P/E Ratio. A P/E of 51.3x leaves little room for execution misses.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

GEV profiles as a value stock while PFE is a declining play — different risk/reward profiles.

GEV is growing revenue faster at 3.8% — sustainability is the question.

PFE generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor SPECIALTY INDUSTRIAL MACHINERY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GEV scores higher overall (55/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE Vernova LLC

INDUSTRIALS · SPECIALTY INDUSTRIAL MACHINERY · USA

GE Vernova LLC, an energy business company, generates electricity.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?